The global next generation sequencing
market is anticipated to reach USD 21.4 billion by 2025, according to a new
report by Grand View Research, Inc. Increasing coverage of NGS is expected to
drive use of precision medicine in oncology from research based setting to
clinical cancer setting. Commercial payers are also engaged in reviewing the
existing and novel tests in order to establish appropriate medical necessity
criteria for their clinical and medical policies.
 |
UK
NGS market revenue, by technology, 2013 - 2024 (USD Million)
|
Moreover, improved understanding of
the genetic markers of virulence and resistance provided by next generation
sequencing is expected to drive demand of the technology in infectious disease
diagnosis.
In depth research report on Next
Generation Sequencing (NGS) Market
Further Key Findings from the Report
suggest:
·
Oncology accounted for
the dominant share owing to phase-resolved and unambiguous results obtained by
using single assay systems, and analysis program.
·
Targeted resequencing
dominated the market owing to its associated benefits such as implementation of
the technique such as lower turnaround time and more manageable data sets.
·
Academic usage of NGS
accounted for the largest share with respect to market revenue by end uses and
is anticipated to maintain its dominance.
·
Higher adoption of this
technology and platforms in university projects is expected to support the
estimated share.
·
Asia Pacific is estimated
to witness the fastest growth over the forecast period owing to expected
routing of a considerable portion of whole genome sequencing requirements
herein.
·
Key players operating in
the NGS market include Illumina Inc., Agilent Technologies, BGI, Pacific
Biosciences, Qiagen, Roche, Thermo Fischer Scientific, and Oxford Nanopore
Technologies Ltd.
·
Endeavors adopted by
participants are such as acquisition of Enzymatics by Qiagen acquired solutions
in order to enhance the product portfolio with respect to reagents needed in
preparatory steps.
Grand View Research has segmented the
NGS market on the basis of application, technology, workflow, and end use:
NGS Outlook, by Application (Revenue, USD Million; 2014 - 2025)
·
Reproductive Health
o NIPT
o PGT
o Newborn/Genetic Screening
·
Oncology
·
HLA Typing/Immune System
Monitoring
·
Metagenomics,
Epidemiology & Drug Development
·
Agrigenomics &
Forensics
·
Consumer Genomics
·
Clinical Investigation
o Idiopathic Diseases
o Inherited Diseases
o Infectious Diseases
o Non-Communicable / Other Diseases
NGS Outlook, by Technology (Revenue, USD Million; 2014 - 2025)
·
Targeted Sequencing
Analysis
o DNA Based Targeted Sequencing Analysis
o RNA Based Targeted Sequencing Analysis
·
Whole Genome Sequencing
·
Whole Exome Sequencing
NGS Outlook, by Workflow (Revenue, USD Million; 2014 - 2025)
·
Pre-sequencing
o NGS Library Preparation Kits
o NGS Semi-automated Library Preparation
o NGS Automated Library Preparation
o Clonal Amplification
·
Sequencing
o Data Analysis
o Primary Data Analysis
o Secondary Data Analysis
o Tertiary Data Analysis
NGS Outlook, by End-use (Revenue, USD Million; 2014 - 2025)
·
Academic Research
·
Clinical Research
·
Hospitals & Clinics
·
Pharma & Biotech
Entities
·
Other Users
NGS Outlook, by Region (Revenue, USD Million; 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o China
o Japan
·
Latin America
o Brazil
·
Middle East & Africa
o South Africa
Browse more research reports of this
category:
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment